Full Logo No Tagline Color
Donations
Donations
Urogenital tumors

Project Group Urogenital Tumors

The study group strengthens research on urogenital tumors with innovative studies on prostate, testicular, urothelial and kidney cancer.

Ongoing Studies

Recruitment completed

SAKK 06/19

Neoadjuvant local immunotherapy plus atezolizumab in localized operable bladder cancer

SAKK 08/23

Can combination therapy with darolutamide delay the progression of metastatic castration-resistant prostate cancer?
Recruitment completed

SAKK 01/18

SAKK 01/18 Reduced-intensity radio-chemotherapy in patients with stage IIA/B seminoma (testicular cancer). A multicenter, open-label phase II study with two patient groups.
Recruitment completed

SAKK 96/12

SAKK 96/12 - Prevention of symptomatic skeletal complications with denosumab administered every 4 weeks versus every 12 weeks

Closed studies

SAKK 01/10

Mild chemotherapy followed by reduced radiotherapy just as effective, but tolerated much better than conven-tional treatment

SAKK 06/14

Immunotherapy with BCG-VPM1002BC in patients with recurrent non-muscle invasive bladder cancer after conventional BCG therapy

SAKK 09/10

Dose intensified radiotherapy in patients with prostate cancer and PSA progression after prostatectomy

Project Group Urogenital Tumors

The project group has developed considerably in recent years. Many studies have been activated and various successful publications have been published. The group has significantly increased patient recruitment.

The study portfolio will be supplemented by a study on salvage radiotherapy in patients with localized prostate cancer, a perioperative study with a combination of tumor checkpoint inhibitor chemotherapy in localized bladder cancer and a new study on metastatic renal cell carcinoma with an innovative design. With the planned studies, our group not only offers promising studies for all prostate cancer stages, but also important studies for patients with testicular carcinoma, urothelial carcinoma and renal cell carcinoma, thus covering the most important research areas in the field of urogenital tumors.